Quarter Ended 31 March, 2020 Page 1 Executive Summary Unit : Million baht 2020 2019 Total revenues * 4,506.78 4,014.33 492.45 12.3 Total cost and expenses * 2,522.92 2,311.10 211.82 9.2 Gain (Loss) on
investors’ confidence about the company. This debenture issuance was aimed to enhance the company’s financial status and innovative power flagship’s goal by driving the financial cost down which will reflect
previous year by 0.79 percent, due to the increase in the cost of raw materials and increase in selling and administrative expenses, as well as increase in cost from long holiday period during the Songkran
excellent service and develop fixed-mobile-contents convergence (FMC) strategies to deliver a superior experience for our customers. The business sector recovered well in 2Q22 and benefited from the
hospitals and medical equipment that will support continuous growth momentum in demand for medical devices in Thailand. 4 Due to growth medical device business, the Company plans to develop new products as
on the dept cost structure analysis for the investment in the biogas power plant project of Aukkrarawat that the Board of Directors has considered additional facts and the study of the change in cost
objective of the termination of this leasehold rights was the ESTATE has intention to develop their new project on this land and to reduce the cost of the Company from recognizing project cost since 2014 when
Procedures Governing the Disclosure of Information and Other Acts of a Listed Company. 2. AFS provides the business administration and support to the oversea subsidiaries in order to grow and develop AFS
the Company’s managements and operations. 2) Announcement of JV agreements with Tokyo Tatemono Asia Pte Ltd. (“Tokyo Tatemono”) to jointly develop 2 luxury condominium projects in Sathorn 12 and in